The First Oral PCSK9 Drug Changes the Cholesterol Treatment Conversation
FDA approval of the first oral PCSK9 inhibitor adds a once-daily option for adults who need greater LDL reduction, but it does not replace individualized cardiovascular care.
Aug 1, 2026






